Pfizer asks Brazil’s health regulator for emergency use of drug for complications of Covid

According to the company, tests conducted in Brazil with tofacitinib indicate a "lower risk of death or respiratory failure".

RIO DE JANEIRO, BRAZIL - Pfizer says it has requested from ANVISA the emergency use of the drug tofacitinib to treat patients who had pneumonia caused by covid-19.

The pharmaceutical company has been conducting clinical trials with the drug in conjunction with Albert Einstein Hospital in 15 Brazilian medical centers. According to Pfizer, the medication was tested in 289 patients who had pneumonia caused by covid-19.

"The research showed that among adult patients admitted with pneumonia resulting from Covid-19, tofacitinib led to a lower risk of death or respiratory failure," Pfizer said in a statement about the comparison . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?